Deregulation of signal-transduction pathways in cancer cells is a general feature, and much effort has been made in order to develop chemotherapeutic agents that efficiently inhibit the activity of the kinases mediating the intracellular transduction of these signals, such as AKT or kinases of the MAPK and SRC families (reviewed in [136–138]). Here, SRC is linked to cancer.